Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FIT-039 是一种选择性和 ATP 竞争性的口服活性 CDK9 抑制剂,对CKD9/cyclin T1的IC50为 5.8 μM。它抑制HSV-1(IC50为 0.69 μM),HSV-2,人腺病毒和人CMV 的复制。它可抑制耐药性HSV 和其他 DNA 病毒,是有前途的抗病毒药物。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 263 | 现货 | ||
5 mg | ¥ 613 | 现货 | ||
10 mg | ¥ 978 | 现货 | ||
25 mg | ¥ 1,950 | 现货 | ||
50 mg | ¥ 3,120 | 现货 | ||
100 mg | ¥ 4,630 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 676 | 现货 |
产品描述 | FIT-039 is a selective and ATP-competitive, orally active inhibitor of CDK9( IC50 : 5.8 μM;CDK9/cyclin T1). FIT-039 inhibits replication of HSV-1 (IC50 of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a promising antiviral agent for inhibiting drug-resistant HSVs and other DNA viruses. |
靶点活性 | HSV1:0.69 μM, CDK9-CyclinT1:5.8 μM |
体外活性 | FIT-039 inhibits HPV replication and expression of E6 and E7 viral oncogenes, restoring tumor suppressors p53 and pRb in HPV+?cervical cancer cells. The therapeutic effect of FIT-039 was demonstrated in CIN model of an organotypic raft culture, where FIT-039 suppressed HPV18-induced dysplasia/hyperproliferation with reduction in viral load. FIT-039 also repressed growth of HPV16+, but not HPV-?cervical cancer xenografts without any significant adverse effects. Safety and pharmacokinetics of FIT-039 were confirmed for systemic and topical routes[1]. |
细胞实验 | Examined FIT-039 for its effect on HPV gene expression in HPV+ cervical cancer cells.?Primary keratinocytes monolayer and organotypic raft culture models were used to evaluate HPV viral replication and cervical intraepithelial neoplasia (CIN) phenotypes.?Preclinical pharmacokinetics and toxicity tests for FIT-039 were also conducted.?Finally, the anti-HPV effect of FIT-039 was further examined in vivo, using HPV+ cervical cancer xenografts[1] |
分子量 | 315.41 |
分子式 | C17H18FN3S |
CAS No. | 1113044-49-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (95.11 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1705 mL | 15.8524 mL | 31.7048 mL | 79.2619 mL |
5 mM | 0.6341 mL | 3.1705 mL | 6.341 mL | 15.8524 mL | |
10 mM | 0.317 mL | 1.5852 mL | 3.1705 mL | 7.9262 mL | |
20 mM | 0.1585 mL | 0.7926 mL | 1.5852 mL | 3.9631 mL | |
50 mM | 0.0634 mL | 0.317 mL | 0.6341 mL | 1.5852 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FIT-039 1113044-49-7 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Others DNA/RNA Synthesis CDK HSV Cytomegalovirus HSV-1 Herpes simplex virus transcription FIT 039 Inhibitor DNA Cyclin dependent kinase CDK9 CMV mRNA FIT039 viruses antiviral inhibit orally polymerase-II HSV-2 inhibitor